Literature DB >> 25549552

Synthesis and molecular modelling studies of 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors.

Yvonnick Loidreau1, Emmanuel Deau1, Pascal Marchand2, Marie-Renée Nourrisson2, Cédric Logé2, Gaël Coadou1, Nadège Loaëc3, Laurent Meijer4, Thierry Besson5.   

Abstract

This paper reports the design and synthesis of a novel series of 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines via microwave-assisted multi-step synthesis. A common precursor of the whole series, 3-amino-5-bromothieno[2,3-b]pyridine-2-carbonitrile, was rapidly synthesized in one step from commercially-available 5-bromo-2-chloronicotinonitrile. Formylation with DMF-DMA led to (E)-N'-(5-bromo-2-cyanothieno[2,3-b]pyridin-3-yl)-N,N-dimethylformimidamide (4) which was conveniently functionalized at position 8 by palladium-catalyzed Suzuki-Miyaura cross-coupling to introduce a heteroaromatic ring. High-temperature formamide-mediated cyclization of the cyanoamidine intermediate gave seventeen 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines. The inhibitory potency of the final products was evaluated against five protein kinases (CDK5/p25, CK1δ/ε, GSK3α/β, DYRK1A and CLK1) and revealed that 8-(2,4-dichlorophenyl)pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine 1g specifically inhibits CK1δ/ε and CLK1 (220 and 88 nM, respectively) while its 7-(2,4-dichlorophenyl)pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine isomer 10 showed no activity on the panel of tested kinases. Molecular modelling of 10 and 1g in the ATP binding sites of CK1δ/ε and CLK1 showed that functionalization at position 7 of pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines is likely to induce a steric clash on the CK1δ/ε P-loop and thus a complete loss of inhibitory activity.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Kinase inhibitors; Microwave-assisted chemistry; Pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4-amines

Mesh:

Substances:

Year:  2014        PMID: 25549552     DOI: 10.1016/j.ejmech.2014.12.038

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  9 in total

Review 1.  DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.

Authors:  Arnaud Duchon; Yann Herault
Journal:  Front Behav Neurosci       Date:  2016-06-03       Impact factor: 3.558

2.  Efficient Synthesis and Antimicrobial Evaluation of Pyrazolopyranopyrimidines in the Presence of SBA-Pr-SO3H as a Nanoporous Acid Catalyst.

Authors:  Ghodsi Mohammadi Ziarani; Faezeh Aleali; Negar Lashgari; Alireza Badiei; Ali Abolhasani Soorki
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

3.  Development of Kinase Inhibitors via Metal-Catalyzed C⁻H Arylation of 8-Alkyl-thiazolo[5,4-f]-quinazolin-9-ones Designed by Fragment-Growing Studies.

Authors:  Florence Couly; Marine Harari; Carole Dubouilh-Benard; Laetitia Bailly; Emilie Petit; Julien Diharce; Pascal Bonnet; Laurent Meijer; Corinne Fruit; Thierry Besson
Journal:  Molecules       Date:  2018-08-29       Impact factor: 4.411

4.  Synthesis of Bioactive 2-(Arylamino)thiazolo[5,4-f]-quinazolin-9-ones via the Hügershoff Reaction or Cu- Catalyzed Intramolecular C-S Bond Formation.

Authors:  Damien Hédou; Carole Dubouilh-Benard; Nadège Loaëc; Laurent Meijer; Corinne Fruit; Thierry Besson
Journal:  Molecules       Date:  2016-06-18       Impact factor: 4.411

5.  Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents.

Authors:  Anne Cecília Nascimento da Cruz; Dalci José Brondani; Temístocles I Talo de Santana; Lucas Oliveira da Silva; Elizabeth Fernanda da Oliveira Borba; Antônio Rodolfo de Faria; Julianna Ferreira Cavalcanti de Albuquerque; Sylvie Piessard; Rafael Matos Ximenes; Blandine Baratte; Stéphane Bach; Sandrine Ruchaud; Francisco Jaime Bezerra Mendonça Junior; Marc-Antoine Bazin; Marcelo Montenegro Rabello; Marcelo Zaldini Hernandes; Pascal Marchand; Teresinha Gonçalves da Silva
Journal:  Pharmaceuticals (Basel)       Date:  2019-11-17

6.  Novel Pyridothienopyrimidine Derivatives: Design, Synthesis and Biological Evaluation as Antimicrobial and Anticancer Agents.

Authors:  Eman M Mohi El-Deen; Manal M Anwar; Amina A Abd El-Gwaad; Eman A Karam; Mohamed K El-Ashrey; Rafika R Kassab
Journal:  Molecules       Date:  2022-01-26       Impact factor: 4.411

7.  First Metal-Free Synthesis of Tetracyclic Pyrido and Pyrazino Thienopyrimidinone Molecules.

Authors:  Mohammed Aounzou; Joana F Campos; Mohammed Loubidi; Sabine Berteina-Raboin
Journal:  Molecules       Date:  2018-05-11       Impact factor: 4.411

8.  Exploring Kinase Inhibition Properties of 9H-pyrimido[5,4-b]- and [4,5-b]indol-4-amine Derivatives.

Authors:  Yvonnick Loidreau; Carole Dubouilh-Benard; Marie-Renée Nourrisson; Nadège Loaëc; Laurent Meijer; Thierry Besson; Pascal Marchand
Journal:  Pharmaceuticals (Basel)       Date:  2020-05-09

9.  Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one, a Promising Inhibitor of DYRK1A.

Authors:  Corinne Fruit; Florence Couly; Rahul Bhansali; Malini Rammohan; Mattias F Lindberg; John D Crispino; Laurent Meijer; Thierry Besson
Journal:  Pharmaceuticals (Basel)       Date:  2019-12-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.